Kendra Klein-Mascia, MD
Ophthalmology · Burlington, MANPI 1205192697
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,340 of the $17,160 with a category attached, or 60.3%. 14 manufacturers reported payments, led by Regeneron at 49.2% of the total. Reporting peaked in 2024 at $8,456 and has fallen 93.2% since, to $579 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $272.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$8K
- Genentech USA, Inc.$5K
- Genentech, Inc.$1K
- Alimera Sciences, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$304
- Neurotech Pharmaceuticals, Inc.$234
- plus $761 from 8 others
Across 3 payments — averaging $19,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$56K
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$10,34060%
- Speaking & faculty fees$1,78010%
- Travel & lodging$1,85211%
- Food & beverage$3,15618%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 9 | $8,448 |
| Genentech USA, Inc. | 14 | $5,227 |
| Genentech, Inc. | 11 | $1,144 |
| Alimera Sciences, Inc. | 2 | $1,042 |
| Regeneron Healthcare Solutions, Inc. | 13 | $304 |
| Neurotech Pharmaceuticals, Inc. | 1 | $234 |
| Novartis | 5 | $172 |
| Alcon | 1 | $167 |
| Astellas Pharma US Inc | 1 | $132 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| Apellis Pharmaceuticals, Inc. | 2 | $105 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Eyepoint US, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$8,256
- VABYSMO$4,885
- Iluvien$1,000
- Non-Covered Product$706
- SUSVIMO$251
- Constellation$167
- Lucentis$146
- Izervay$132
- STELLARIS PC$121
How this compares
$17,160 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 34 | $2,081 |
| Difluprednate | 26 | $1,738 |
| ErythromycinErythromycin Base | 35 | $483 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $406 |
| Brimonidine Tartrate | 40 | $373 |
| Dorzolamide Hcl | 17 | $353 |
| Latanoprost | 30 | $335 |
| Timolol Maleate | 12 | $214 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Burlington
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.